[February 20, 2018]

Farxiga (dapagliflozin; AstraZeneca) Drug Analysis 2017 - ResearchAndMarkets.com

The "Drug analysis: Farxiga" drug pipelines has been added to ResearchAndMarkets.com's offering.

Farxiga (dapagliflozin; AstraZeneca) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion.

Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia. The drug was developed as part of a joint venture between AstraZeneca and Bristol-Myers Squibb. However, AstraZeneca has taken full ownership and marketing responsibilities ater buying its partner's share of the venture.

Key Topics Covered:

List of Figures

Figure 1: Farxiga for type 2 diabetes - SWOT analysis

Figure 2: Drug assessment of Farxiga

Figure 3: Drug assessment scorecard for Farxiga compared to Januvia

Figure 4: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

Figure 5: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

Figure 6: Farxiga for type 1 diabetes - SWOT analysis

Figure 7: Drug assessment of Farxiga in type 1 diabetes

Figure 8: Drug assessment of Farxiga in type 1 diabetes

List of Tables

Table 1: Farxiga franchise products

Table 2: Farxiga drug profile

Table 3: Xigduo drug profile

Table 4: Overview of pivotal trial data for Farxiga in diabetes

Table 5: Key planned and ongoing Phase III clinical trials for Farxiga in diabetes

Table 6: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 7: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 8: Farxiga drug profile

Table 9: Farxiga late-phase trial in type 1 diabetes

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xjhhqh/farxiga?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006294/en/

[ Back To TMCnet.com's Homepage ]